For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.
Ellogon AI B.V. develops AI technology for the diagnosis of cancer immunotherapy and is founded by Efstratios Gavves and Evangelos Kanoulas researchers at the Informatics Institute.

Innovation Fund Noord Holland finances UvA spin-off Ellogon AI B.V. with a loan of 297,000 euros for the development of AI technology for the diagnosis of cancer immunotherapy. Ellogon works together with the Netherlands Cancer Institute. With this financing Ellogon takes an important step in improving the survival rates for cancer patients.